Patients who received etanercept exhibited a greater reduction in MRI-based scores for sacroiliac joint inflammation ( -46.9 % versus -10.9 % ; P < 0.001 ) and spinal inflammation ( -45.4 % versus -33.4 % ; P = 0.04 ) compared with placebo-treated patients at week 12 .